JOSÉ LUIS
GONZÁLEZ LARRIBA
Catedrático de universidad
Hospital Clinic Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (12)
2021
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148
-
Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study
BMC Psychology, Vol. 8, Núm. 1
-
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
Lung Cancer, Vol. 147, pp. 83-90
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
2018
-
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
European Respiratory Journal
-
LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38
2016
-
Lung cancer in women with a family history of cancer: The Spanish female-specific database WORLD07
Anticancer Research, Vol. 36, Núm. 12, pp. 6647-6653
2011
-
Management of lung cancer-associated anaemia: The Spanish Lung Cancer Anaemia Survey (SLCAS)
Clinical and Translational Oncology, Vol. 13, Núm. 5, pp. 328-334
-
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
Annals of Oncology, Vol. 22, Núm. 12, pp. 2646-2653
2009
-
Screening for epidermal growth factor receptor mutations in lung cancer
New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967
2007
-
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: Final results from a phase II study
British Journal of Cancer, Vol. 97, Núm. 9, pp. 1206-1210